FDA advisors unanimously reject Intarcia's embattled type 2 diabetes treatment - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
I2o Therapeutics CEO Kurt Graves set out on Thursday to make a case to a panel of the FDA’s expert advisors that the benefits of his company’s twice-rejected implant to treat type 2 diabetes outweigh its risks — but the committee wasn't convinced. The FDA’s E…